Popular 'Slimming Needle' Drug Linked to Potential 'Eye Stroke' Signal

A recent analysis of U.S. Food and Drug Administration (FDA) adverse event reports has flagged a potential signal for "eye stroke" associated with semaglutide, the active ingredient in the popular weight-loss medication Wegovy. While the number of reported cases of ischemic optic neuropathy (ION) is low – less than 1% of all semaglutide-related reports – and a definitive causal link remains unproven, the findings warrant attention. This development, published in the *British Journal of Ophthalmology*, is being closely watched by health professionals and patients alike. The study examined data from 2017 to 2024, identifying 28 cases of ION among over 31,000 reports involving semaglutide. It's crucial to note that the patient populations using these drugs often have pre-existing conditions such as hypertension, cardiovascular disease, and diabetes, which are themselves significant risk factors for ION. This overlap complicates the task of isolating the drug's specific contribution, if any. As experts emphasize, the FDA database is primarily a signal detection tool, and reports are not independently verified. Therefore, while users should remain vigilant and monitor their vision, there is currently no cause for widespread alarm. Continued observation and further research are essential to clarify the relationship, if any, between semaglutide and ION. This story is particularly relevant to our readers who are increasingly interested in the efficacy and safety of GLP-1 agonists for weight management and diabetes treatment.

“

The hot 'slimming needle' GLP-1 agonist drug Wegovy has a 'stroke signal' in adverse drug reactions, with related cases accounting for less than 1%, and a causal relationship has not yet been confirmed.